Related Experiment Video

Updated: Jun 7, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Management of chronic hepatitis B: status and challenges beyond treatment guidelines

Johannes Wiegand1, Florian van Bömmel, Thomas Berg

  • 1Universitätsklinikum Leipzig, Sektion Hepatologie, Leipzig, Germany.

Seminars in Liver Disease
|October 21, 2010
PubMed

Insights

Current hepatitis B virus (HBV) treatments suppress viral DNA and prevent fibrosis, but do not fully prevent liver cancer. New strategies and markers are needed for optimal treatment timing and patient management.

Area of Science:

  • Hepatology
  • Virology
  • Internal Medicine

Background:

  • Chronic hepatitis B virus (HBV) infection management guidelines exist.
  • Current therapies like interferon and nucleos(t)ide analogues suppress HBV DNA and prevent fibrosis, reducing hepatocellular carcinoma (HCC) risk.

Purpose of the Study:

  • To review strategies for optimizing HBV treatment indication and cessation.
  • To discuss the interpretation of viral markers for improved patient care.
  • To identify patients at high risk for severe HBV outcomes.

Main Methods:

  • Literature review of national and international guidelines.
  • Analysis of therapeutic strategies for chronic HBV infection.
  • Discussion of viral parameter interpretation (HBsAg quantification, HBV genotypes, HBeAg).

Main Results:

  • Suppression of HBV replication does not eliminate HCC risk, even if fibrosis is halted.
  • Optimal timing for initiating and stopping therapy remains a challenge.
  • Identifying high-risk patients is crucial for preventing fatal outcomes.

Conclusions:

  • Further research is needed to refine therapeutic strategies for chronic HBV.
  • Development of more sensitive markers is essential for guiding treatment decisions.
  • Personalized risk assessment is key to managing patients with chronic HBV infection.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...